skip to content

Clinical Trials

MainTitle

Open-Label, 48 Week Extension Study of Elvucitabine in Combination With Background ART For Subjects Who Have Completed Study ACH443-014A

This study has been completed
Sponsor
Achillion Pharmaceuticals


Information provided by (Responsible Party)
Achillion Pharmaceuticals
ClinicalTrials.gov Identifier
NCT00380159

First received: September 21, 2006
Last updated: February 18, 2014
Last Verified: February 2014
History of Changes
Purpose

Purpose

To assess the safety of 48 weeks of treatment with 10 mg of elvucitabine in combination with background ART in subjects who completed protocol ACH443-014A and meet the inclusion and exclusion criteria.

Condition Intervention Phase
HIV-1 Infection

Drug : elvucitabine
Drug : Lamivudine
Drug : Emtricitabine
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label,48 Week Extension Study of Elvucitabine Administered In Combination With Background Antiretroviral Agents in Subjects Who Have Completed 14 Days of Treatment in Protocol ACH443-014A.

Further study details as provided by Achillion Pharmaceuticals:

Primary Outcome Measures

  • To assess the safety of 48weeks of 10mg/QD of elvucitabine in combination with ART [ Time Frame: September 2008 ]
Secondary Outcome Measures:
  • To describe the anti-viral activity of elvucitabine in combination with ART as measured by plasma HIV-1 RNA over 24 weeks [ Time Frame: September 2008 ]

Enrollment: 4
Study Start Date: September 2006
Study Completion Date: January 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)

Detailed Description:

This study is an open-label extension study for subjects who have completed 14 days of treatment in protocol ACH443-014A and meet all inclusion and exclusion criteria. Elvucitabine treatment (10mg) will begin on Day 1 (Day 15 following completion of protocol ACH443-014A) for all consented subjects in combination with background ART as determined by the principal investigator. Subjects will have clinical and laboratory assessments every 2 weeks for the first 8 weeks and then every 4 weeks to week 48.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 60 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • Subjects who have completed 14 days of treatment in ACH443-014A and who, in the investigator's judgment, remain candidates to receive elvucitabine together with background antiretroviral therapy.


Exclusion Criteria:
  • Failure to meet inclusion criteria

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00380159

Locations

United States, Georgia
ARCA
Atlanta, Georgia, United States, 30308
United States, Ohio
ACTU University of Cincinnati
Cincinnati, Ohio, United States, 45242
Dominican Republic
Dr. Salvador B Gautier Hospital
Santo Domindo, Dominican Republic
Germany
EPIMED
Berlin, Germany
immunologische Ambulanz, University Clinic
Bonn, Germany
Klinikum der Universitat zu Koln
Koln, Germany
Spain
Hospital La Paz
Madrid, Spain

Sponsors and Collaborators

Achillion Pharmaceuticals

Investigators

Principal Investigator: Michael Saag, MD Aids Out-Ptient Clinic University of Alabama
Principal Investigator: Richard Pollard, MD Division of ID University of CA Davis
Principal Investigator: Donna Mildvan, MD ACTU Beth Israel Medical Center
Principal Investigator: Judit Fienberg, MD University of Cincinnati
Principal Investigator: D Jayaweera, MD ID Research Unit University of Miami
Principal Investigator: Edwin DeJesus, MD Orlando Immunology Center
Principal Investigator: Melanie Thompson, MD ARCA Atlanta Georgia
More Information

More Information


Responsible Party: Achillion Pharmaceuticals, Inc., Ronald Gugliotti  
ClinicalTrials.gov Identifier: NCT00380159   History of Changes  
Other Study ID Numbers: ACH443-018  
Study First Received: September 21, 2006  
Last Updated: February 18, 2014  

Keywords provided by Achillion Pharmaceuticals:

Extension study to ACH443-014A

Additional relevant MeSH terms:
Lamivudine
Emtricitabine
Anti-Retroviral Agents

ClinicalTrials.gov processed this data on October 17, 2017
This information is provided by ClinicalTrials.gov.